Skip to main content
Respicardia gets $5.1M boost

A private debt placement involving 13 investors has pulled in $5.1 million for Respicardia, bringing the company closer to its target of $6.6 million. The company, which makes the implantable Remede System for treating central sleep apnea, recently found positive results in a trial, which showed 51% of patients achieved a reduction in the number of sleep apnea events per hour.

Full Story: